Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.
Also called NCT03336528
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 180 participants
- Sponsor
- Registry
-
NCT03336528
-
- Other papers using this trial's data
- Degludec hospital trial: A randomized controlled trial comparing insulin degludec U100 and glargine U100 for the inpatient management of patients with type 2 diabetes
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03336528. Randomized; no masking; primary purpose treatment. Start 2018-01-02 (actual); primary completion 2021-03-01 (actual). Results posted on 2022-03-31.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Degludec
- Intervention (Drug)
- Glargine
- Intervention (Drug)
- Aspart
- Lead sponsor
- Emory University
- Collaborator
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct03336528- Content hash
9f29476871c8cb176f570bd5ad17060968c8ba0ea4e5c61176e578eed7a17a60